InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.00
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.79
(
1.05%
)
Bitcoin
65,123.64
(
-2.05%
)
Post# of 252252
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 119075

Sunday, 10/16/2011 1:52:11 PM

Sunday, October 16, 2011 1:52:11 PM

Post# of 252252
Higher Lucentis dose (2mg) is dead but monthly vs. an As-Needed Basis (PRN) perhaps not:

Here not so good news is that the HARBOR study is clearly showing us that high-dose approach with Lucentis will not be an option. We were not able to show the superiority of this high-dose approach and we are still analyzing the data as far as the PRN versus monthly comparison.

See mid page 4: http://www.morningstar.com/earnings/31452276-roche-holding-ag-adr-rhhby-q3-2011.aspx?pindex=4
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up